Cambridge Healthtech Institute’s 3rd Annual

Preclinical and Translational Immuno-Oncology

Predictive Preclinical Models and Translational Strategies for Cancer Immunotherapy

August 28-29, 2018

The recent advancements in immunotherapies, such as immune checkpoint modulators, bispecific antibodies, and adoptive T cell transfer, are shifting the way cancer patients are treated. Rapid development of novel immuno-oncology programs is creating the need for predictive preclinical models and translational strategies to understand combination immunotherapy, study responses and resistance to cancer immunotherapy, and identify novel biomarkers and targets. Please join Cambridge Healthtech Institute’s Third Annual Preclinical and Translational Immuno-Oncology meeting and learn about new clinically-relevant models for screening IO therapies and translational strategies to support clinical IO programs.

Preliminary Agenda


The Role of Genetically Engineered Mouse Models of Cancer in Profiling Novel Immune Targeting Therapies

Elizabeth Hardaker, PhD, Head, Oncology, In Vivo Pharmacology, AstraZeneca

Using Syngeneic Mouse Models for IO Combination Studies

Manfred Kraus, PhD, Director, in vivo Pharmacology, Tumor Cell Biology, Pfizer Oncology

Translational Immuno-Oncology

Niranjan Yanamandra, PhD, Scientific Director, Immuno-Oncology Translational Research, GlaxoSmithKline

Using Mouse Models to Dissect Different Components in the Tumor Microenvironment

Zhao Chen, PhD, Investigator III, Exploratory Immuno-Oncology, Novartis Institute of Biomedical Research

Beyond Genomics: Protein Profiling of Patient-Derived 3D Models for Biomarker Identification

Christoph Sachse, PhD, Site Head Berlin, NMI TT Pharmaservices


Genetic Alterations in CD19 Lead to CD19 Negative Relapse to CAR19 Therapy in Pediatric ALL

Elena Orlando, PhD, Bioinformatics Investigator, Novartis Institutes for BioMedical Research

The Stromal Microenvironment in Cancer Immunology and Immunotherapy

Shannon J. Turley, PhD, Principal Scientist, Cancer Immunology, Genentech

What We Have Learned about Large Scan Genetic Analysis of Tumors in Melanoma Patients Treated with Immune Checkpoint Inhibitors

Ryan J. Sullivan, MD, Assistant Professor, Hematology & Oncology, Massachusetts General Hospital; Assistant Professor, Medicine, Harvard Medical School

Tumor-Mediated Modulation of Immunometabolism as a Mechanism of Immunotherapy Resistance: Implications for Combination Immunotherapy Development

Brent Hanks, MD, PhD, Assistant Professor, Medicine, Duke University School of Medicine

For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute

For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286